Cochleovestibulopathy as a Paraneoplastic Syndrome Linked to Breast Cancer: A Case Study of Two Patients and Review of Existing Literature - Scorecard - MDSpire
Advertisement
Cochleovestibulopathy as a Paraneoplastic Syndrome Linked to Breast Cancer: A Case Study of Two Patients and Review of Existing Literature
Clinical Scorecard: Cochleovestibulopathy as a Paraneoplastic Syndrome Linked to Breast Cancer: A Case Study of Two Patients and Review of Existing Literature
At a Glance
Category
Detail
Condition
Paraneoplastic cochleovestibulopathy (PCVP), an atypical paraneoplastic neurological syndrome causing sudden or rapidly progressive sensorineural hearing loss and vestibular dysfunction.
Key Mechanisms
Autoimmune-mediated neuronal damage associated with malignant tumors, often with detectable paraneoplastic antibodies targeting neuronal antigens.
Target Population
Patients presenting with sudden or progressive bilateral sensorineural hearing loss and vertigo, especially those with underlying or suspected malignancies such as breast cancer.
Care Setting
Specialized tertiary care centers with access to audiological, neurological, oncological, and immunological diagnostic and therapeutic resources.
Key Highlights
PCVP presents with sudden or rapidly progressive bilateral sensorineural hearing loss and vestibular symptoms unresponsive to steroid therapy.
Diagnosis is challenging due to atypical clinical features and rarity; often associated with breast adenocarcinoma and other malignancies.
Treatment of underlying malignancy and immunotherapy may alleviate vestibular symptoms but hearing loss often persists.
Guideline-Based Recommendations
Diagnosis
Consider PCVP in patients with sudden or progressive bilateral sensorineural hearing loss and vertigo unresponsive to steroids.
Perform comprehensive audiological assessments including pure-tone audiometry, brainstem auditory evoked potentials, and otoacoustic emissions.
Conduct imaging studies (CT, MRI, PET/CT) to exclude structural causes and identify underlying malignancies.
Test serum and cerebrospinal fluid for paraneoplastic antibodies and neuronal autoantibodies, although specific antibodies may be undetectable.
Management
Treat underlying malignancy promptly with surgery, endocrine therapy, or other oncological interventions as appropriate.
Administer immunotherapy such as intravenous immunoglobulin (IVIG) and corticosteroids to address autoimmune mechanisms.
Consider cochlear implantation for severe hearing loss, though hearing recovery may be limited.
Monitoring & Follow-up
Regular audiological follow-up to assess hearing status and vestibular function.
Serial imaging to monitor tumor response to therapy.
Monitor autoimmune antibody titers and neurological symptoms to evaluate treatment efficacy.
Risks
Misdiagnosis leading to inappropriate steroid treatment without addressing underlying malignancy.
Progressive irreversible hearing loss despite immunotherapy and cancer treatment.
Potential complications related to immunosuppressive therapy and oncological treatments.
Patient & Prescribing Data
Patients with PCVP associated with breast cancer presenting with sensorineural hearing loss and vertigo.
Immunotherapy (IVIG and corticosteroids) may provide partial relief of vestibular symptoms but often does not improve hearing loss; endocrine therapy or surgical excision of breast cancer is essential for tumor control.
Clinical Best Practices
Maintain high clinical suspicion for PCVP in patients with unexplained bilateral sensorineural hearing loss and vestibular symptoms, especially with known or suspected malignancy.
Use multimodal diagnostic approaches combining audiology, imaging, and immunological testing.
Coordinate multidisciplinary care involving neurology, oncology, otolaryngology, and immunology specialists.
Educate patients about the potential for persistent hearing loss despite treatment and discuss rehabilitative options such as hearing aids or cochlear implants.
